C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma

OBJECTIVES: Immune checkpoint blockade (IO) has revolutionised the treatment of metastatic renal cell carcinoma (mRCC). Early C‐reactive protein (CRP) kinetics, especially the recently introduced CRP flare‐response phenomenon, has shown promising results to predict IO efficacy in mRCC, but has only...

Descripción completa

Detalles Bibliográficos
Autores principales: Klümper, Niklas, Schmucker, Philipp, Hahn, Oliver, Höh, Benedikt, Mattigk, Angelika, Banek, Severine, Ellinger, Jörg, Heinzelbecker, Julia, Sikic, Danijel, Eckstein, Markus, Strauß, Arne, Zengerling, Friedemann, Hölzel, Michael, Zeuschner, Philip, Kalogirou, Charis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648498/
https://www.ncbi.nlm.nih.gov/pubmed/34925829
http://dx.doi.org/10.1002/cti2.1358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648498/
https://www.ncbi.nlm.nih.gov/pubmed/34925829
http://dx.doi.org/10.1002/cti2.1358

Ejemplares similares